Get your Pfizer COVID-19 vaccine. Walk-ins welcome! Mon., Wed., Fri.: 8 a.m. - 5 p.m. and Tues., Thurs.: 8 a.m. - 7 p.m. >

Multicenter Phase II Trial of Durvalumab (MEDI4736) With Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial)

Investigator: Jenny Chang, MD

Study Coordinator: Juan Morales Viera

Status: Enrolling

ClinicalTrials.gov Number: NCT03820141

Phone: 786.803.2333

Protocol Number: Pro00020917

Description

The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.
More to Explore
Search Clinical Trials
Join a Clinical Trial
Clinical Research Support Services for Investigators
Weill Cornell Medical College Clinical Trials